Photodynamic compound inactivation of SARS-CoV-2 vaccineThe animal testing has started
Under the terms of the agreement, Theralase and PHAC are collaborating on the development and optimization of a COVID-19 vaccine by treating the SARS-CoV-2 virus grown on cell lines with Theralase's patented photodynamic compounds and then light activating it with Theralase's proprietary TLC-3000A light technology to inactivate the virus and create the fundamental building blocks of a COVID-19 vaccine. This inactivated virus would then be purified and used to inoculate naive animals, followed by a challenge with the SARS-CoV-2 virus to ascertain the efficacy of the vaccine. The project is entitled, "Photodynamic compound inactivation of SARS-CoV-2 vaccine," and is expected to commence in mid-April, 2021.